Ph. Eur. monograph 1472 establishes the baseline identity and purity envelope for sodium hyaluronate, including intrinsic viscosity by Ph. Eur. 2.2.9, protein, nucleic acid, and loss on drying. In ophthalmic preparations intended for canine keratoconjunctivitis sicca and equine corneal re-epithelialisation, the veterinary-grade API is dissolved in a phosphate-buffered vehicle at 0.10–0.40% w/v. The selected fraction has an intrinsic viscosity between 1.8 m³/kg and 2.5 m³/kg; lower intrinsic viscosity gives faster drainage from the ocular surface, while higher intrinsic viscosity increases terminal filling pressure and reduces sterile-filter flux. The resulting solution displays shear-thinning rheology, with apparent viscosity at 0.1 s⁻¹ approximately one order of magnitude higher than at 100 s⁻¹. This permits retention during the inter-blink interval without creating excessive lid friction. Osmolality is adjusted to 270–320 mOsm/kg with sodium chloride and confirmed by freezing-point depression per USP <785>. The pH is maintained at 6.5–7.5; below 6.0, acid-catalysed hydrolysis of the glycosidic linkage reduces intrinsic viscosity when retested per Ph. Eur. 2.2.9, while above 7.8 oxidative degradation can accelerate in the presence of residual peroxide from buffer components.

Terminal steam sterilisation is not used for high-molecular-weight ophthalmic grades because moist heat at 121°C for 15 minutes produces chain scission and an unacceptable loss of viscoelastic function. Aseptic filtration through a 0.22 µm membrane is feasible only at the lower end of the concentration range; above 0.30% w/v, membrane flux declines steeply and published manufacturer data for this specific configuration is limited. Bulk solution is therefore filtered in-line through a prefilter and sterilising-grade membrane before filling into low-density polyethylene or glass ophthalmic containers under laminar flow. The finished product is tested for sterility per USP <71> and for bacterial endotoxins per Ph. Eur. 2.6.14; any excursion beyond the approved limit requires batch rejection because endotoxin can penetrate compromised corneal epithelium. Preservative selection is restricted: cationic agents such as chlorhexidine may form insoluble complexes with the anionic carboxylate groups, while oxidative preservatives can depolymerise the chain. Benzalkonium chloride at low concentration is used in some multi-dose veterinary eye drops, but compatibility must be confirmed by zeta potential measurement and real-time viscosity stability data. Long-term stability of the vehicle is controlled by storage at 2–8°C in sealed containers; accelerated storage at 25°C/60% RH for 6 months is used to bracket temperature excursions during distribution. A reduction of more than 10% in intrinsic viscosity from the release value is treated as a significant degradation event under the authorised stability specification.

What limits 0.22 µm membrane throughput in high-molecular-weight injectable grades?

Intra-articular products for equine and canine osteoarthritis are formulated at 10–20 mg/mL sodium hyaluronate in isotonic phosphate-buffered saline, with injection volumes from 2 mL for small canine joints to 6 mL for equine carpal or fetlock joints. The solution behaves as a non-Newtonian viscoelastic fluid; after dilution with synovial fluid, the complex viscosity at 10 s⁻¹ and 37°C determined by cone-and-plate rheometry provides a more meaningful release parameter than dynamic viscosity at a single shear rate. Grades with intrinsic viscosity below 2.0 m³/kg are cleared more rapidly from the joint space, while grades above 3.0 m³/kg produce syringing resistance that can lead to cavitation and shear-induced molar-mass loss during aseptic filling. Published species-specific clearance curves for molecular weight fractions are limited, so the formulation is normally bracketed by measurement of intrinsic viscosity per Ph. Eur. 2.2.9 and by in vitro hyaluronidase degradation rate in synovial fluid.

Sterile filtration of these solutions through a 0.22 µm polyethersulfone or PVDF sterilising-grade membrane is the principal process bottleneck. The high solution viscosity at 20–25°C reduces flux, and increasing differential pressure to compensate causes shear at the membrane pore that can permanently lower molecular weight. Filling lines are therefore operated with low-shear rotary piston pumps or peristaltic pumps below 300 rpm, and product-contact tubing is sized to keep wall shear below 500 s⁻¹. No terminal steam regimen is applied because the required F₀ cannot be tolerated by the polymer; in-process bioburden control before the sterilising filter is mandatory. Batch-to-batch variance in intrinsic viscosity of more than ±5% around the approved release value changes filling pressure and filter flux on the same line, requiring pump speed re-qualification. Single-use filter capsules from different suppliers can show different adsorption losses; polyethersulfone is preferred over nylon because nylon may bind hyaluronate through hydrogen bonding. Bacterial endotoxin release testing uses Ph. Eur. 2.6.14, and particulate contamination is evaluated under USP <788>. A batch with visible gel particles after filtration is rejected; the cause is usually local gel hydration at the filter inlet rather than microbial contamination.

Compression, granulation, and the hygroscopicity boundary in oral solid dosage forms

Sodium hyaluronate for tablets, capsules, and oral granules is rarely used at high loading because the powder becomes hygroscopic above 60% RH and equilibrium moisture can exceed 10% w/w at 25°C/60% RH. Direct compression is the preferred process when the drug load is 10–50 mg per unit. A 16-station rotary press operating at 30–60 rpm with a precompression force of 4–8 kN and main compression force of 12–20 kN can produce tablets with acceptable tensile strength if the granulate moisture is kept below 8% w/w and the compression environment is dehumidified to below 40% RH. Powder flow is characterised by bulk and tapped density per USP <616> and compressibility index per USP <1174>; a compressibility index above 30% indicates the need for dry granulation or a glidant such as colloidal silicon dioxide at 0.5–1.5% w/w. Magnesium stearate is limited to 0.5–1.0% w/w and blend time to 3–5 minutes; longer lubrication times reduce tablet hardness.

Wet granulation with water is technically possible but not preferred because sodium hyaluronate forms a gel layer on contact with water, causing non-uniform granule growth in high-shear mixers. If a wet process is required, a binder solution of 5% w/v povidone in isopropanol or ethanol is used, followed by fluid-bed drying with inlet air dew point below −20°C. Fluid-bed granulation yields granules with d50 150–250 µm and friability below 2%. Capsule filling on an intermittent-motion dosator machine requires granule Carr index below 20% and residual moisture below 5% w/w to prevent powder sticking to the dosator pin. Basic excipients that raise microenvironmental pH above 8.0 are not used because alkaline hydrolysis of the glycosidic bond accelerates; formulations containing magnesium oxide or sodium bicarbonate require barrier coating if their inclusion is unavoidable. Dissolution testing is of limited discriminatory value for high-molecular-weight hyaluronate; disintegration time per USP <701> and water content per USP <921> are more process-relevant release controls. If incoming powder moisture exceeds 8% w/w, vacuum drying at 60°C for 4 hours is applied before weighing.

In feed premix operations, coated sodium hyaluronate granules with d50 150–250 µm are blended into a maltodextrin or lactose carrier at addition rates of 0.5–5.0 kg/tonne complete feed. A double-ribbon mixer running at 15 rpm for 10 minutes typically produces a coefficient of variation below 5% when active concentration is measured by NIR spectroscopy using a calibration validated per ISO 12099. Longer mixing times above 20 minutes are avoided because the coating on the granule surface abrades, generating fines below 45 µm that segregate during silo discharge and reduce content uniformity at the point of feeding. Pneumatic conveying of the finished premix should be limited to distances below 10 m and air velocities below 20 m/s; higher velocity conveys cause electrostatic adhesion to pipe walls and active loss at bends. The premix is stored in sealed aluminium-lined bags with desiccant because moisture ingress above 60% RH causes surface hydration and particle agglomeration that cannot be reversed by subsequent dry mixing.

When the premix is intended for incorporation into extruded companion-animal kibble, the thermal load of the extrusion barrel must be considered. Sodium hyaluronate undergoes chain scission at elevated temperatures; exposure to 120°C for more than 10 minutes under 15–20% moisture can reduce intrinsic viscosity below the label claim. Consequently, the active is applied post-extrusion via a vacuum coater using a liquid suspension or low-temperature top-dress rather than incorporated into the preconditioner. Published data for the specific survival rate after each extrusion configuration is limited, so process validation is required with extruder temperature profiling and molecular weight analysis per Ph. Eur. 2.2.9 before commercial batches are released.

Post-operative lavage solutions: residence time, serosal coverage, and sterility boundaries

Sodium hyaluronate solutions at 0.1–0.5% w/v are used in veterinary surgery as viscoelastic lavage fluids and temporary adhesion barriers, particularly after abdominal surgery in dogs and horses. The polymer adsorbs onto damaged mesothelial surfaces through non-specific electrostatic interactions; the carboxylate groups provide hydration and reduce fibrin bridges between opposing serosal layers. The solution is instilled before abdominal closure and left in place for a residence time of 15–60 minutes; immediate suction removes the protective film and negates the anti-adhesion function. The molecular weight should be above 1.0 MDa because lower fractions produce insufficient surface retention and are cleared by lymphatic uptake more quickly; however, published data for specific veterinary adhesion prevention configurations is limited.

Sterility and endotoxin controls follow parenteral principles even when the route is intra-operative. The bulk solution is aseptically filtered through a 0.22 µm membrane and filled into single-use vials; sterility testing is performed per USP <71> and bacterial endotoxin testing per Ph. Eur. 2.6.14. The pH is adjusted to 6.5–7.5 with phosphate or citrate buffers, and chloride content is kept isotonic to avoid serosal irritation. Cytotoxicity and irritation endpoints are assessed on packaging and process residues under ISO 10993-5 and ISO 10993-10 when regulatory submissions cover device-drug combinations. A major incompatibility exists with cationic antiseptics: combining sodium hyaluronate with chlorhexidine gluconate above 0.05% w/v leads to precipitation and loss of the protective coating. The solution should not be mixed with hyaluronidase-containing preparations in the same irrigation tray because enzymatic depolymerisation begins within minutes at 37°C.

When sodium hyaluronate is incorporated into oromucosal gels or oral pastes for feline gingivostomatitis and canine oral ulceration, the polymer concentration is limited to 0.5–2.0% w/v because higher loadings produce a yield stress above 20 Pa and prevent extrusion from a 10 mL polyethylene dosing syringe at 25°C. The gel is prepared by hydrating the powder in a glycerol-water vehicle under vacuum, avoiding high-shear rotor-stator mixing that can reduce molecular weight. Rheological characterisation with a cone-and-plate or parallel-plate rheometer at 25°C and 37°C verifies that the elastic modulus G′ exceeds the viscous modulus G″ within the linear viscoelastic range at 1 Hz, which is required for mucosal retention. The pH is buffered to 6.8–7.2 to avoid acid-induced degradation and to reduce stinging on ulcerated tissue. Because water activity is high, the formulation is preserved with a non-cationic agent and subjected to antimicrobial effectiveness testing per USP <51>. The product is packaged in aluminium barrier tubes; storage below 25°C and protection from light are specified to limit oxidative depolymerisation.

Manufacturing experience on pilot lines shows that air entrapment during vacuum mixing is a common batch failure; if the vessel vacuum is released too quickly, microbubbles remain in the gel and alter both visual appearance and yield stress. Deaeration at −0.8 bar for at least 30 minutes after powder hydration is required. The raw powder is sieved before weighing to remove agglomerates above 250 µm, because undispersed agglomerates act as nucleation points for syneresis during storage at 40°C accelerated conditions. Published data for specific veterinary oral wound-healing outcomes is limited, and efficacy studies use investigator-blinded scoring rather than in vitro release testing alone.

Reconstituting lyophilised powders within the post-aseptic window

Sodium hyaluronate powders and granules destined for injectable or ophthalmic reconstitution are lyophilised in Type I borosilicate glass vials from a bulk solution of 1.0–2.0% w/v. The freeze-dried cake must have residual moisture below 2.0% w/w by Karl Fischer titration per USP <921>; higher moisture accelerates glass transition collapse and reduces reconstitution clarity. The lyophilisation cycle separates the product from terminal sterilisation, so the powder is filled aseptically and the rubber stopper is tested for fragmentation and self-sealing per USP <381>. Reconstitution with water for injection at 20–25°C should produce a clear, colourless solution within 10 minutes without shaking; vigorous agitation introduces air bubbles and shear that lower molecular weight. The reconstituted solution contains no preservative and is used within 4 hours at 2–8°C unless the marketing authorisation specifies otherwise.

The lyophilised format is chosen for products that cannot tolerate the moisture and thermal load of terminal sterilisation, but it creates a different risk: reconstitution errors. If the solvent volume is less than specified, the resulting hypertonic solution may cause injection-site pain or corneal epithelial damage; if the solvent volume is greater, the therapeutic viscosity and residence time are lost. Syringe filters should not be used after reconstitution of high-molecular-weight grades unless specifically validated, because the combined effects of filter shear and adsorption can remove a significant fraction of the polymer. Batch release includes identity by infrared spectroscopy, intrinsic viscosity per Ph. Eur. 2.2.9, and particulate matter per USP <788> after reconstitution. Any visible gel particles or fibres indicate inadequate lyophilisation or stopper coring and require batch rejection.